BioNTech SE (BNTX)

BioNTech SE Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	11,664	13,875	1,693	1,210	519.15
Short-Term Investments	5,166	461.3	495	137.2	1.68
Cash & Cash Equivalents	16,830	14,336	2,188	1,347	520.83
Cash Growth	17.39%	555.32%	62.36%	158.70%	26.47%
Receivables	2,156	7,146	12,382	165.5	11.91
Inventory	357.7	439.6	502.5	64.1	11.72
Other Current Assets	184	0.4	0.4	89.9	15.69
Total Current Assets	19,527	21,922	15,072	1,667	560.15
Property, Plant & Equipment	971.6	821.1	520.4	326	148.06
Long-Term Investments	1,260	86.7	35.7	0	0
Goodwill and Intangibles	1,167	219.7	202.4	163.5	89.43
Other Long-Term Assets	81.3	229.6	0	162.2	0
Total Long-Term Assets	3,479	1,357	758.5	651.7	237.5
Total Assets	23,006	23,279	15,831	2,319	797.65
Accounts Payable	354	204.1	160	102.3	20.5
Deferred Revenue	751.8	125.5	195.1	371.5	190.69
Current Debt	443.3	821.1	1,320	83.2	15.66
Other Current Liabilities	521.4	1,800	1,806	49	-88.71
Total Current Liabilities	2,071	2,951	3,482	606	138.14
Long-Term Debt	229.8	182.3	177.7	262.5	68.9
Other Long-Term Liabilities	460.1	90.6	277.8	78.3	97.11
Total Long-Term Liabilities	689.9	272.9	455.5	340.8	166.01
Total Liabilities	2,760	3,224	3,937	946.8	304.16
Total Debt	673.1	1,003	1,498	345.7	84.56
Debt Growth	-32.92%	-33.02%	333.32%	308.81%	35.34%
Retained Earnings	19,763	18,833	9,883	-409.6	-424.83
Shareholders' Equity	20,246	20,056	11,894	1,372	493.49
Net Cash / Debt	16,157	13,333	689.7	1,002	436.27
Net Cash / Debt Growth	21.18%	1833.16%	-31.15%	129.61%	24.88%
Working Capital	17,457	18,971	11,591	1,061	422.01
Book Value Per Share	85.17	82.53	48.67	6.05	2.18

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).